348 related articles for article (PubMed ID: 34845311)
1. Selective KRAS G12C inhibitors in non-small cell lung cancer: chemistry, concurrent pathway alterations, and clinical outcomes.
Palma G; Khurshid F; Lu K; Woodward B; Husain H
NPJ Precis Oncol; 2021 Nov; 5(1):98. PubMed ID: 34845311
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development-a narrative review.
Santarpia M; Ciappina G; Spagnolo CC; Squeri A; Passalacqua MI; Aguilar A; Gonzalez-Cao M; Giovannetti E; Silvestris N; Rosell R
Transl Lung Cancer Res; 2023 Feb; 12(2):346-368. PubMed ID: 36895930
[TBL] [Abstract][Full Text] [Related]
3. CodeBreaK 200: Sotorasib (AMG510) Has Broken the
Brazel D; Kim J; Ou SI
Lung Cancer (Auckl); 2023; 14():31-39. PubMed ID: 37101896
[TBL] [Abstract][Full Text] [Related]
4. Targeted Therapies for Previously "Undruggable" KRAS-Mutated Non-Small Cell Lung Cancer: A Review of Sotorasib and Adagrasib.
Mausey N; Halford Z
Ann Pharmacother; 2024 Jun; 58(6):622-635. PubMed ID: 37700573
[TBL] [Abstract][Full Text] [Related]
5. Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun.
Bungaro M; Novello S; Passiglia F
Curr Treat Options Oncol; 2022 Dec; 23(12):1699-1720. PubMed ID: 36394791
[TBL] [Abstract][Full Text] [Related]
6. Targeting
Ji J; Wang C; Fakih M
Onco Targets Ther; 2022; 15():747-756. PubMed ID: 35837349
[TBL] [Abstract][Full Text] [Related]
7. From bench to bedside: current development and emerging trend of KRAS-targeted therapy.
Chen Y; Liu QP; Xie H; Ding J
Acta Pharmacol Sin; 2024 Apr; 45(4):686-703. PubMed ID: 38049578
[TBL] [Abstract][Full Text] [Related]
8. Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers.
Cekani E; Epistolio S; Dazio G; Cefalì M; Wannesson L; Frattini M; Froesch P
Cancers (Basel); 2022 Aug; 14(17):. PubMed ID: 36077640
[TBL] [Abstract][Full Text] [Related]
9. The Path to Personalized Treatment in KRAS-Mutant Non-Small Cell Lung Cancer: A Review of Targeted Therapies and Immunotherapy.
Shu CL; Liu YL
Cancer Manag Res; 2022; 14():3485-3492. PubMed ID: 36561983
[TBL] [Abstract][Full Text] [Related]
10. Sotorasib as First-Line Treatment for Advanced KRAS G12C-Mutated Non-Small Cell Lung Carcinoma: A Case Report.
Iska S; Alley EW
Case Rep Oncol; 2023; 16(1):177-181. PubMed ID: 37008835
[TBL] [Abstract][Full Text] [Related]
11. Editorial: Recent Approval of Sotorasib as the First Targeted Therapy for KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC).
Parums DV
Med Sci Monit; 2022 Nov; 28():e938746. PubMed ID: 36317327
[TBL] [Abstract][Full Text] [Related]
12. Emerging Therapies in Kirsten Rat Sarcoma Virus (+) Non-Small-Cell Lung Cancer.
Karachaliou A; Kotteas E; Fiste O; Syrigos K
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672529
[TBL] [Abstract][Full Text] [Related]
13. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches.
Reck M; Carbone DP; Garassino M; Barlesi F
Ann Oncol; 2021 Sep; 32(9):1101-1110. PubMed ID: 34089836
[TBL] [Abstract][Full Text] [Related]
14. Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation.
Zheng X; Luo J; Liu W; Ashby CR; Chen ZS; Lin L
Drugs Today (Barc); 2022 Apr; 58(4):175-185. PubMed ID: 35412531
[TBL] [Abstract][Full Text] [Related]
15. KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments.
Koga T; Suda K; Fujino T; Ohara S; Hamada A; Nishino M; Chiba M; Shimoji M; Takemoto T; Arita T; Gmachl M; Hofmann MH; Soh J; Mitsudomi T
J Thorac Oncol; 2021 Aug; 16(8):1321-1332. PubMed ID: 33971321
[TBL] [Abstract][Full Text] [Related]
16. Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integrative Treatments and Future Perspectives.
Li JX; Li RZ; Ma LR; Wang P; Xu DH; Huang J; Li LQ; Tang L; Xie Y; Leung EL; Yan PY
Front Pharmacol; 2022; 13():875330. PubMed ID: 35517800
[TBL] [Abstract][Full Text] [Related]
17. Targeting
Désage AL; Léonce C; Swalduz A; Ortiz-Cuaran S
Front Oncol; 2022; 12():796832. PubMed ID: 35251972
[TBL] [Abstract][Full Text] [Related]
18. TEAD Inhibitors Sensitize KRAS
Tammaccaro SL; Prigent P; Le Bail JC; Dos-Santos O; Dassencourt L; Eskandar M; Buzy A; Venier O; Guillemot JC; Veeranagouda Y; Didier M; Spanakis E; Kanno T; Cesaroni M; Mathieu S; Canard L; Casse A; Windenberger F; Calvet L; Noblet L; Sidhu S; Debussche L; Moll J; Valtingojer I
Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111311
[TBL] [Abstract][Full Text] [Related]
19. Recent progress in targeting KRAS mutant cancers with covalent G12C-specific inhibitors.
Rathod LS; Dabhade PS; Mokale SN
Drug Discov Today; 2023 May; 28(5):103557. PubMed ID: 36934967
[TBL] [Abstract][Full Text] [Related]
20. Adagrasib: a novel inhibitor for
Guo MZ; Marrone KA; Spira A; Rosner S
Future Oncol; 2023 May; 19(15):1037-1051. PubMed ID: 37133216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
